Consistent with several cohort observation of elevated C5a expression in the serum of AMD patients [14-16], our results support the notion that C5a may be one of the factors contributing to the elevated serum IL-22 and IL-17 levels in AMD patients. This evidence concerns the gene IL22 and age-related macular degeneration.